Tag: Press Releases

Biodesix, Inc., a molecular diagnostics company that discovers and commercializes blood-based diagnostic tests to improve outcomes for patients with cancer, today announced that the company was named the 216th fastest-growing private company in America in the 2015 Inc.500|5000 list.

VeriStrat blood-based proteomic test continues to gain coverage across United States for patients with non-small cell lung cancer (NSCLC)

Biodesix Inc., a molecular diagnostics company that researches, develops and commercializes rapid, blood-based tests for precision medicine in oncology, announced today that the company increased the size of its offering of series E preferred shares in a follow-on sale. In addition to the $27 million of series E shares sold from 2013 through 2015, the…

Blood-based proteomic test now covered for more than 115 Million lives in US

  Diagnostic deemed medically necessary to guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC)

Lung cancer diagnostic deemed medically necessary to guide treatment decisions

Biodesix to Fund Proof of Concept Study 

Independent Phase III Data to Be Presented at the 2013 ASCO Annual Meeting

  Biodesix, Inc., a molecular diagnostics company advancing the development of innovative products for personalizing medicine, announced today that the company closed on $8.8 million in a follow-on sale of its Series D preferred shares.  All funds were provided by existing shareholders of the company.  The investment will be used for ongoing development of the…

Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced…